Expression of the nociceptin/orphanin FQ receptor in the intestinal mucosa of IBS patients

Li,Lu; Dong,Lei; Wang,Shenhao

doi:10.3892/etm.2013.1186

Expression of the nociceptin/orphanin FQ receptor in the intestinal mucosa of IBS patients

Authors:
- Lu Li
- Lei Dong
- Shenhao Wang
View Affiliations

Affiliations: Department of Gastroenterology, The Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
Published online on: June 27, 2013 https://doi.org/10.3892/etm.2013.1186
Pages: 679-683

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nociceptin/orphanin FQ (N/OFQ) and the N/OFQ peptide (NOP) receptor play important roles in regulating gastrointestinal function. To assess whether the NOP receptor is implicated in the etiopathogenesis of irritable bowel syndrome (IBS), we measured the levels of NOP receptor mRNA and protein in the jejunal and colonic tissues of healthy subjects and patients with diarrhea-predominant IBS (D-IBS) and constipation‑predominant IBS (C-IBS). Mucosal biopsies were obtained from the jejunum and colon of patients diagnosed with D-IBS and C-IBS by the Rome III criteria and from healthy control subjects. The expression of NOP receptor mRNA was measured quantitatively using quantitative PCR (qPCR) and NOP protein expression was assayed immunohistochemically using a rabbit monoclonal antibody to OFQ. NOP receptor mRNA was detected in the jejunum and colon of healthy subjects and was more highly expressed in the jejunum than in the colon. Expression was lower in the jejunum and colon of patients with D-IBS; however, it was similar in patients with C-IBS and healthy subjects. The numbers of OFQ-positive cells in the jejunum and colon were similar among the three groups. The NOP receptor may be involved in the regulation of intestinal movement in healthy individuals. Its involvement in the pathophysiology of IBS may depend on whether the IBS is constipation- or diarrhea-predominant.

View Figures

View References

1	Neal KR, Hebden J and Spiller R: Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 314:779–782. 1997. View Article : Google Scholar
2	Drossman DA, Li Z, Andruzzi E, et al: U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 38:1569–1580. 1993. View Article : Google Scholar : PubMed/NCBI
3	Dean BB, Aguilar D, Barghout V, et al: Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 11(Suppl 1): S17–S26. 2005.PubMed/NCBI
4	El-Serag HB: Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord. 3(Suppl 2): S3–S11. 2003.PubMed/NCBI
5	El-Serag HB, Olden K and Bjorkman D: Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 16:1171–1185. 2002. View Article : Google Scholar
6	Longstreth GF, Bolus R, Naliboff B, et al: Impact of irritable bowel syndrome on patients’ lives: development and psychometric documentation of a disease-specific measure for use in clinical trials. Eur J Gastroenterol Hepatol. 17:411–420. 2005.
7	Hulisz D: The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm. 10:299–309. 2004.PubMed/NCBI
8	Pace F, Molteni P, Bollani S, et al: Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroentrol. 38:1031–1038. 2003. View Article : Google Scholar : PubMed/NCBI
9	Kanazawa M, Palsson OS, Thiwan SI, et al: Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol. 103:2550–2561. 2008. View Article : Google Scholar : PubMed/NCBI
10	Olszewski PK, Grace MK, Fard SS, et al: Central nociceptin/orphanin FQ system elevates food consumption by both increasing energy intake and reducing aversive responsiveness. Am J Physiol Regul Integr Comp Physiol. 299:R655–R663. 2010. View Article : Google Scholar : PubMed/NCBI
11	Przydzial MJ and Heisler LK: Nociceptin/orphanin FQ peptide receptor as a therapeutic target for obesity. Mini Rev Med Chem. 8:796–811. 2008. View Article : Google Scholar : PubMed/NCBI
12	Matsushita H, Ishihara A, Mashiko S, et al: Chronic intracerebroventricular infusion of nociceptin/orphanin FQ produces body weight gain by affecting both feeding and energy metabolism in mice. Endocrinology. 150:2668–2673. 2009. View Article : Google Scholar : PubMed/NCBI
13	Agostini S, Eutamene H, Broccardo M, et al: Peripheral anti-nociceptive effect of nociceptin/orphanin FQ in inflammation and stress-induced colonic hyperalgesia in rats. Pain. 141:292–299. 2009. View Article : Google Scholar : PubMed/NCBI
14	Drossman DA and Dumitrascu DL: Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 15:237–241. 2006.
15	Bunzow JR, Saez C, Mortrud M, et al: Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett. 347:284–288. 1994. View Article : Google Scholar : PubMed/NCBI
16	Mogil JS and Pasternak GW: The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev. 53:381–415. 2001.PubMed/NCBI
17	Anton B, Fein J, To T, Li X, Silberstein L and Evans CJ: Immunohistochemical localization of ORL-1 in the central nervous system of the rat. J Comp Neurol. 368:229–251. 1996. View Article : Google Scholar : PubMed/NCBI
18	Florin S, Leroux-Nicollet I, Meunier JC and Costentin J: Autoradiographic localization of [³H] nociceptin binding sites from telencephalic to mesencephalic regions of the mouse brain. Neurosci Lett. 230:33–36. 1997.
19	Wang JB, Johnson PS, Imai Y, et al: cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett. 348:75–79. 1994. View Article : Google Scholar : PubMed/NCBI
20	Nothacker HP, Reinscheid RK, Mansour A, et al: Primary structure and tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci USA. 93:8677–8682. 1996. View Article : Google Scholar : PubMed/NCBI
21	Mollereau C, Simons MJ, Soularue P, et al: Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc Natl Acad Sci USA. 93:8666–8670. 1996. View Article : Google Scholar : PubMed/NCBI
22	Calo’ G, Guerrini R, Rizzi A, Salvadori S and Regoli D: Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol. 129:1261–1283. 2000.PubMed/NCBI
23	Fox DA and Burks TF: Roles of central and peripheral mu, delta and kappa receptors in the mediation of gastric acid secretory effects in the rat. J Pharmacol Exp Ther. 244:456–462. 1988.PubMed/NCBI
24	Improta G and Broccardo M: Effect of selective mu 1, mu 2 and delta 2 opioid receptor agonists on gastric functions in the rat. Neuropharmacology. 33:977–981. 1994. View Article : Google Scholar : PubMed/NCBI
25	Osinski MA and Brown DR: Orphanin FQ/nociceptin: a novel neuromodulator of gastrointestinal function. Peptides. 21:999–1005. 2000. View Article : Google Scholar : PubMed/NCBI
26	Li HY, Yan X, Xue QL, et al: Effects of nociceptin/orphanin FQ on rats with cathartic colon. World J Gastroenterol. 13:141–145. 2007. View Article : Google Scholar : PubMed/NCBI
27	Broccardo M, Guerrini R, Petrella C and Improta G: Gastrointestinal effects of intracerebroventricularly injected nociceptin/orphaninFQ in rats. Peptides. 25:1013–1020. 2004. View Article : Google Scholar : PubMed/NCBI
28	Takahashi T, Mizuta Y and Owyang C: Orphanin FQ, but not dynorphin A, accelerates colonic transit in rats. Gastroenterology. 119:71–79. 2000. View Article : Google Scholar : PubMed/NCBI
29	Kunkel EJ, Campbell JJ, Haraldsen G, et al: Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med. 192:761–768. 2000. View Article : Google Scholar
30	Alemayehu A, Lock KR, Coatney RW and Chou CC: L-NAME, nitric oxide and jejunal motility, blood flow and oxygen uptake in dogs. Br J Pharmacol. 111:205–212. 1994. View Article : Google Scholar : PubMed/NCBI
31	Kamel HM, Willmott N, McNicol AM and Toner PG: The use of electron microscopy and immunocytochemistry to characterise spontaneously-arising, transplantable rat tumors. Virchows Arch B Cell Pathol Incl Mol Pathol. 57:11–18. 1989. View Article : Google Scholar : PubMed/NCBI
32	Looi LM, Yap SF and Cheah PL: Correlation between oestrogen receptor protein expression in infiltrating ductal carcinoma of the breast by immunohistochemistry and cytosol measurements. Ann Acad Med Singap. 26:750–753. 1997.
33	Ford AC, Talley NJ, Schoenfeld PS, Quigley EM and Moayyedi P: Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 58:367–378. 2009. View Article : Google Scholar : PubMed/NCBI
34	Ohman L and Simrén M: Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 7:163–173. 2010. View Article : Google Scholar : PubMed/NCBI
35	Lü N, Han M, Yang ZL, Wang YQ, Wu GC and Zhang YQ: Nociceptin/orphanin FQ in PAG modulates the release of amino acids, serotonin and norepinephrine in the rostral ventromedial medulla and spinal cord in rats. Pain. 148:414–425. 2010.PubMed/NCBI
36	Yazdani A, Takahashi T, Bagnol D, Watson SJ and Owyang C: Functional significance of a newly discovered neuropeptide, orphanin FQ, in rat gastrointestinal motility. Gastroenterology. 116:108–117. 1999. View Article : Google Scholar : PubMed/NCBI